Alzheimer's disease

While AC Immune SA (NASDAQ: ACIU)’s crenezumab Alzheimer's treatment could be a breakthrough if trials prove successful, the faraway approval and launch timelines for the drug could mean the stock will see few catalysts over the next 12 months, according to Credit Suisse. The Analyst...

"Age is just a number, not a state of mind or a reason for any type of particular behavior." -Cecelia Ahern Alzheimer's disease is the sixth leading cause of death in the U.S., although recent estimates indicate it may now be the third most common cause of death, behind heart disease...

Pain Therapeutics, Inc. (NASDAQ: PTIE) shares took center stage Monday, offering pleasure rather than pain to those investing in the company. The shares of the clinical-stage biopharma company gap-opened up at $4.20, adding over 12 percent from the previous session's close of $3.74....

Corium International (NASDAQ: CORI) shares have been white hot over the past 10 days, rising more than 30 percent since the company reported positive preliminary results in the clinical study of its Corplex Donepezil Alzheimer's Disease (AD) product candidate. The Data In a pilot...

Alzheimer's has proven to be one of the most stubborn diseases known to modern medicine. An incurable, devastating illness that inspires frustration — even anger — against and from the scientific community itself, which has failed to develop new, effective therapies. Susanne...

Neurotrope Inc (OTC: NTRP), a clinical stage biopharmaceutical company, may have found through its drug Bryostatin a unique solution to addressing Alzheimer's, one of the last major diseases with no cure. Benzinga recently spoke with CEO Dr. Susanne Wilke, ahead of her appearance at the...

Shares of AC Immune Ltd (NASDAQ: ACIU), a medical biotechnology company that focuses on the treatment of Alzheimer's disease (AD) and other neurodegenerative diseases, soared higher by more than 23 percent after the company's partner Genentech published an editorial. AC Immune and Genentech have...

Shares of Biogen Inc (NASDAQ: BIIB) were trading up almost 1.2 percent on Thursday afternoon shortly before the closing bell. The movement apparently comes on the back of updated and embargoed aducanumab titration data leaked from the 9th Clinical Trials on Alzheimer's Disease (CTAD) congress...

Eli Lilly and Co (NYSE: LLY) fell steeply Wednesday after it announced that its Alzheimer's disease treatment candidate solanezumab didn't meet the primary endpoint in a late-stage clinical trial dubbed EXPEDITION3. In a sympathy move, Biogen Inc (NASDAQ: BIIB) also traded notably lower. Is the...

Wall Street analysts have shown a bullish sentiment towards pharmaceutical and healthcare companies that focus on the treatment of Alzheimer's disease. A few days ago, BMO Capital Market's hosted a conference call with Dr. Dennis Selkoe, a leading Alzheimer's diseases researcher....